Arachidonic acid metabolism in purified human lung mast cells.
Arachidonic acid metabolism has been explored in preparations of purified human lung mast cells prelabeled with arachidonic acid (AA). Cells were of 83 to greater than 96% purity, and each experiment was performed with four to six different preparations of mast cells. After overnight culture of the purified cells in the presence of 3H-AA, followed by extensive washing in buffer, mast cell uptake of labeled AA was 61.4 +/- 14.8 pmol/10(6) cells with 21 +/- 2.4% of the label in phospholipids, 73 +/- 2.1% in neutral lipids, and 3.6 +/- 0.8% as free AA. Analysis of the distribution of radioactivity in phospholipid classes revealed 51.4 +/- 5.5% of the label in phosphatidylcholine, 14.5 +/- 1.6% in phosphatidylinositol, 12.0 +/- 3.0% in phosphatidylethanolamine, and 9.1 +/- 2.4% in sphingomyelin, with the rest in other phospholipid classes. Challenge of these cells with an optimal concentration of anti-IgE led to the release of 20 +/- 4.0% of cellular histamine and to a reduction in labeled phosphatidylcholine and phosphatidylinositol to 75.5 +/- 8.8% and 84.2 +/- 4.5% of the control levels, respectively, (p less than 0.05); anti-IgE challenge produced no statistically significant change in the quantities of other labeled phospholipids. Activation of human lung mast cells with anti-IgE led to the release of 3.4 +/- 1.3% of the cellular 3H as AA and AA metabolites (1.5 +/- 0.6% as unmetabolized AA) in conjunction with 16 +/- 4.3% of the cellular histamine. Although activation of human lung mast cells with ionophore A23187 caused 70 +/- 1.1% histamine release, a similar quantity of AA and AA metabolites was released (a total of 4.0 +/- 0.8% with 2.3 +/- 1.5% as unmetabolized AA). Analysis of the released metabolites by liquid scintillation spectrometry after high performance liquid chromatography separation showed that approximately equal amounts of metabolites were produced after mast cell activation with anti-IgE and ionophore A23187. In this series of experiments approximately equal amounts of cyclooxygenase and lipoxygenase products were generated.(ABSTRACT TRUNCATED AT 400 WORDS)
D000888:Antibodies, Anti-Idiotypic / Q000502:physiology; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000096:biosynthesis / Q000378:metabolism*; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids; D007073:Immunoglobulin E / Q000276:immunology / Q000502:physiology; D007213:Indomethacin / Q000494:pharmacology; D007975:Leukotriene B4 / Q000096:biosynthesis; D008168:Lung / Q000166:cytology*; D008407:Mast Cells / Q000276:immunology / Q000378:metabolism*; D015230:Prostaglandin D2; D011457:Prostaglandins D / Q000096:biosynthesis; D013189:SRS-A / Q000096:biosynthesis
D000888:Antibodies, Anti-Idiotypic; D001095:Arachidonic Acids; D006893:Hydroxyeicosatetraenoic Acids; D011457:Prostaglandins D; D013189:SRS-A; C026408:anti-IgE antibodies; D007975:Leukotriene B4; D016718:Arachidonic Acid; D007073:Immunoglobulin E; C022022:5-hydroxy-6,8,11,14-eicosatetraenoic acid; D015230:Prostaglandin D2; D007213:Indomethacin